arrow_back Civic Audit
Share share

Prohibiting Delay of Generic and Biosimilar Drugs: More Affordable Medicines

This act aims to increase the availability of more affordable generic and biosimilar drugs. It prohibits brand-name drug companies from paying generic companies to delay the market entry of their cheaper alternatives. This means citizens can expect lower drug prices and more choices, positively impacting their personal finances and access to healthcare.
Key points
Prohibits payments to delay the market entry of cheaper generic and biosimilar drugs.
Aims to increase competition and lower drug prices, leading to savings for patients.
The Federal Trade Commission (FTC) gains new powers to prosecute such unfair practices and impose significant penalties.
article Official text account_balance Process page notifications_active Track this Bill
Status: Placed on Calendar
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_S_1096
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2025-03-24
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Preserve Access to Affordable Generics and Biosimilars Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1096.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-03-24.

What are the main provisions?

Key points include:

  • Prohibits payments to delay the market entry of cheaper generic and biosimilar drugs.
  • Aims to increase competition and lower drug prices, leading to savings for patients.
  • The Federal Trade Commission (FTC) gains new powers to prosecute such unfair practices and impose significant penalties.
What is the specific legal status?

The current status is Placed on Calendar.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Economy Courts and Law